Evidence map›Paper›PMID 31152702›Full record

ArticleEuropean journal of pharmacology2019

Pharmacological characterizations of the 'legal high' fluorolintane and isomers.

Jason Wallach, Tristan Colestock, Julià Agramunt, Matt D B Claydon, Michael Dybek, Nadine Filemban, Muhammad Chatha, Adam L Halberstadt, Simon D Brandt, David Lodge and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Jason WallachDepartment of Pharmaceutical Sciences, University of the Sciences, Philadelphia, PA, USA; Substance Use Disorders Institute, University of the Sciences, Philadelphia, PA, USA. Electronic address: j.wallach@usciences.edu.
Tristan ColestockDepartment of Pharmaceutical Sciences, University of the Sciences, Philadelphia, PA, USA.
Julià AgramuntCentre for Synaptic Plasticity, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, United Kingdom.
Matt D B ClaydonCentre for Synaptic Plasticity, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, United Kingdom.
Michael DybekDepartment of Chemistry and Biochemistry, University of the Sciences, Philadelphia, PA, USA.
Nadine FilembanDepartment of Pharmaceutical Sciences, University of the Sciences, Philadelphia, PA, USA.
Muhammad ChathaDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
Adam L HalberstadtDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA; Research Service, VA San Diego Healthcare System, San Diego, CA, USA.
Simon D BrandtSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, United Kingdom.
David LodgeCentre for Synaptic Plasticity, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, United Kingdom.
Zuner A BortolottoCentre for Synaptic Plasticity, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, United Kingdom.
Adeboye AdejareDepartment of Pharmaceutical Sciences, University of the Sciences, Philadelphia, PA, USA; Department of Chemistry and Biochemistry, University of the Sciences, Philadelphia, PA, USA.
University of the Sciences · USUniversity of Bristol · GBLiverpool John Moores University · GBUniversity of California, San Diego · USVA San Diego Healthcare System · US

Funding

The Next Generation of Hallucinogens: A New Class of Synthetic Psychoactive DrugsR01DA041336 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HALBERSTADT, ADAM L. · 2017 to 2020
$1.4M
Medical Research Council MR/R010919/1NIDA NIH HHS R01 DA041336
6 · The paper itself

Abstract

1,2-Diarylethylamines represent a class of molecules that have shown potential in the treatment of pain, epilepsy, neurodegenerative disease and depression. Examples include lefetamine, remacemide, and lanicemine. Recently, several 1,2-diarylethylamines including the dissociatives diphenidine, methoxphenidine and ephenidine as well as the opioid MT-45, have appeared as 'research chemicals' or 'legal highs'. Due to their recent emergence little is known about their pharmacology. One of these, 1-[1-(2-fluorophenyl)-2-phenylethyl]pyrrolidine (fluorolintane, 2-F-DPPy), is available for purchase with purported dissociative effects intended to resemble phencyclidine (PCP) and ketamine. To better understand this emerging class, pharmacological investigations were undertaken for the first time on fluorolintane and its five aryl-fluorine-substituted isomers. In vitro binding studies revealed high affinity for N-methyl-D-aspartate (NMDA) receptors with fluorolintane (K

Indexed as

AnimalsBinding SitesDose-Response Relationship, DrugExcitatory Postsynaptic PotentialsHippocampusIsomerismLong-Term PotentiationMalePyrrolidinesRatsReceptors, N-Methyl-D-AspartatefluorolintanepyrrolidinePyrrolidinesReceptors, N-Methyl-D-AspartateDiphenidineFluorolintaneKetamineLegal highNMDA receptor antagonist

Identifiers

PMID31152702
PMCPMC6899220
OpenAlexW2947100202

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.